Groupe Grimaud Chooses Affymetrix Genotyping Arrays for Poultry Breeding Business
24 February 2016 - 10:30PM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) announced today that one of the
world’s largest producers of breeding chickens – Roussay,
France-based Groupe Grimaud – will use the Axiom® genotyping
platform from Affymetrix in its genomic selection and poultry
breeding program. The Grimaud Novogen and Hubbard divisions will be
incorporating the Affymetrix technology, and the company is already
using a rabbit genotyping array from Affymetrix. Array
manufacturing consistency with no SNP dropout or batch-to-batch
variation, along with Affymetrix’ expert customization
capabilities, were cited as factors influencing the purchase
decision.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160224005505/en/
Affymetrix will develop multiple custom chicken genotyping
microarrays in 96- and 384-array formats for the Axiom 384HT
platform. Grimaud will also use the expert design arrays in
Affymetrix’ portfolio. The catalog and custom genotyping arrays for
poultry will enable Groupe Grimaud to select chickens for desired
traits and also help identify candidates from pure-bred lines to
move forward into production.
“Groupe Grimaud is committed to sustainable agriculture and
meeting our customers’ needs through genetic technologies that
improve the performance and quality of our products while keeping
the diversity of the gene pool in our poultry breeding program,”
said Olivier Demeure, Ph.D., chief scientific officer for Groupe
Grimaud. “The genotyping tools provided by Affymetrix and the
genomic selection techniques in our poultry breeding program will
be used to accelerate selection of genetic production traits and to
improve our products for traits such as robustness. Through the
Groupe Grimaud multi-species portfolio, the same developments will
also be applicable to other products such as pig (Choice Genetics
Division), rabbit (Hypharm Division), and duck (Grimaud Frères
Sélection Division).”
“This large-scale industrial use of Axiom genotyping arrays
validates yet again the potential of the platform and Affymetrix’
commitment to help strengthen the worldwide food supply,” said
Laurent Bellon, Ph.D., senior vice president and general manager,
Genotyping Business Unit at Affymetrix. "The Axiom 384HT platform
is the leading solution for genomic selection in poultry and we are
very happy to have Groupe Grimaud tap into Affymetrix’ expertise in
designing custom genotyping arrays for avian genomes and use this
platform for their genetic selection program.”
Agricultural genotyping solutions from Affymetrix offer animal
genotyping customers customized, cost-effective, and automated
genotyping tools for the highly accurate identification,
validation, and screening of genetic markers associated with
desired genetic traits. Affymetrix is the leader in customization
of agriculture genotyping arrays and also offers catalog arrays for
a variety of plants and animals that were designed under the Expert
Design Program.
For more information about the Axiom genotyping platform for
agrigenomics applications, please visit
www.affymetrix.com/agrigenotyping
About Groupe Grimaud
Groupe Grimaud is a primarily family-owned entity, whose
registered offices are located in Roussay (49), France. The company
specializes in animal genetic selection and biopharmacy. As a
result of acquisitions, alliances, and internal growth over the
last ten years, Groupe Grimaud has been ranked second in the world
for multi-species animal genetic selection. With 2,200 staff
members, Groupe Grimaud provides services in over 100 countries.
Subsidiaries in production and breeding have been established in 15
countries on four continents. For more information, please visit
http://www.grimaud.com
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of benchtop research into
clinical and routine use for human health and wellness. Affymetrix
provides leadership and support, partnering with customers in
pharmaceutical, diagnostic, and biotechnology companies, as well as
leading academic, government, and nonprofit research institutes in
their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
94,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, San
Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees
and maintains sales and distribution operations worldwide. For more
information about Affymetrix, please visit www.affymetrix.com
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2015, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo, and Axiom
trademarks are the property of Affymetrix, Inc. All other
trademarks are the property of their respective owners.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160224005505/en/
Affymetrix, Inc.Media Contact:Mindy Lee-Olsen,
408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comORInvestor
Contact:Doug Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024